Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ProQuad Vaccine BLA Review Extended To September

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has extended its review of Merck's measles, mumps, rubella and varicella vaccine ProQuad by three months until Sept. 30

You may also be interested in...



Merck Proquad MMR/V Combo Vaccine Clears FDA With Approval For Second Round MMR Vaccination

The measles, mumps, rubella and varicella vaccine will be priced at $120.25 for an individual single-dose vial.

Merck Proquad MMR/V Combo Vaccine Clears FDA With Approval For Second Round MMR Vaccination

The measles, mumps, rubella and varicella vaccine will be priced at $120.25 for an individual single-dose vial.

Merck Vaccines Unit To Be Headed By U.S. Human Health President McGlynn

Margaret McGlynn will succeed Adel Mahmoud in overseeing four launches planned for 2005-2006, including HPV vaccine Gardasil.

Topics

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel